# Vilon

> Synthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.

- Also known as: Lys-Glu, KE dipeptide
- Class: Immune, Bioregulators, Longevity
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/vilon

## Overview

Vilon is a synthetic dipeptide (Lys-Glu) developed as a defined-sequence "Cytogen" successor to the thymic extract Thymalin. Russian research studied it as a tissue bioregulator of immune function and an aging-axis peptide.

Vilon is one of the simplest members of the Khavinson short-peptide bioregulator class — a two–amino-acid sequence (Lys-Glu) intended to reproduce, in a defined synthetic form, the immune-regulating activity attributed to the thymic extract Thymalin.

The class hypothesis is that such short peptides penetrate the cell and bind specific promoter regions of DNA, modulating transcription in a tissue-selective way. Reported studies examined effects on immune indices, chromatin activation, and lifespan in model organisms. As with the rest of the class, the literature is concentrated in one research tradition and lacks large independent trials; it is not FDA-approved.

## Mechanism

Proposed direct gene-regulatory binding (short peptide–DNA interaction) modulating immune-related gene expression.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular weight | 275.3 Da |

## Sequence

```
KE
```

## Research areas

Studied in: Immune modulation, Aging biology, Peptide bioregulators.

Guides on this site:

- [Longevity & Aging](https://www.americanpeptide.com/research-areas/longevity-aging): Peptides studied across the aging axis — senescence, NAD+, and resilience.
- [Immune & Inflammation](https://www.americanpeptide.com/research-areas/immune-inflammation): Thymic and host-defense peptides studied for immune modulation.
- [Peptide Bioregulators](https://www.americanpeptide.com/research-areas/bioregulators): Short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series.

## Key research

- Gene-regulatory hypothesis — the originating group reported that Lys-Glu can interact with DNA and de-condense heterochromatin, proposed as the basis for transcriptional activation of age-silenced genes.
- Immune indices — studied for normalization of immune and interferon parameters in aged animal models.
- Lifespan models — reported increases in mean lifespan in rodents in originating-group studies; not independently replicated.
- Evidence quality — single-tradition, mostly preclinical; findings are preliminary.

## FAQs

### What is Vilon?

Vilon is a synthetic Lys-Glu dipeptide studied in Russia as a defined-sequence immune and aging bioregulator — the short-peptide successor to the thymic extract Thymalin.

### How is it thought to work?

The class hypothesis is that the short peptide enters the cell and binds specific DNA promoter regions, modulating gene expression in a tissue-selective way. This mechanism is proposed, not firmly established.

### Is the evidence strong?

No — it is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Vilon, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples](https://clinicaltrials.gov/study/NCT02580799) — COMPLETED · NCT02580799

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/vilon
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.